Akeso Inc (AKESF)

$22.03 +0.36 (1.64%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 1,800
Avg Vol 3,466
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 75%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also develo...

Industry: Biotechnology
Sector: Healthcare
Phone: 86 760 8987 3998
Fax: 86 760 8987 3900
Address:
No. 6, Shennong Road, Torch Development Zone, Zhongshan, China
ChillPill1972
ChillPill1972 Aug. 11 at 11:04 AM
$SMMT $AKESF Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy In previous studies focused on extensive-stage SCLC (ES-SCLC), ivonescimab has demonstrated its ability to prolong progression-free survival (PFS), combining the synergistic benefits of PD-1/L1 inhibitors and anti-angiogenic agents. Ivonescimab is a cornerstone in Akeso's "IO 2.0" strategy, and Akeso has already initiated a series of Phase III and Phase II clinical trials investigating ivonescimab as a first-line treatment across multiple cancer indications. The initiation of a Phase III study of ivonescimab for LS-SCLC is another key step in extending Akeso's "IO 2.0" approach to earlier stages of lung cancer.
0 · Reply
ChillPill1972
ChillPill1972 Jul. 24 at 2:01 PM
$SMMT $AKESF Akeso having a big month of new trials starting across multiple cancer types which should compliment Summits efforts nicely.
0 · Reply
ChillPill1972
ChillPill1972 Jul. 4 at 11:58 AM
$SMMT $AKESF had a great week, sitting at alltime high. Happy 4th of July!!
0 · Reply
ChillPill1972
ChillPill1972 Jul. 3 at 3:23 PM
$SMMT $AKESF PR today: (not related to the summit news) Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy https://www.prnewswire.com/news-releases/akesos-first-bispecific-adc-trop2nectin4-adc-enters-clinical-trials-strengthening-leadership-in-ioadc-2-0-strategy-302497499.html
0 · Reply
ChillPill1972
ChillPill1972 Jul. 3 at 11:30 AM
$SMMT $AKESF with a strong finish to their day and an alltime high. US markets close at 1pm today for a long weeknd perhaps we get some news soon.
0 · Reply
JRobb66
JRobb66 Jun. 14 at 9:54 AM
$AKESF does this trade? Or what’s the story here
0 · Reply
Bornjever
Bornjever Apr. 25 at 8:14 PM
$AKESF so some persons wrote these guys got FDA approval but not true correct??? After they get stage two from FDA then a year to get stage 3 and then 8 months to get PDUFA. It takes forever. But folks can die or go to China.
0 · Reply
jvj19
jvj19 Apr. 25 at 5:56 PM
$SMMT why isn’t $AKESF trending after they received FDA approval?
3 · Reply
jvj19
jvj19 Apr. 25 at 5:28 PM
$SMMT $AKESF is open to trade.
0 · Reply
PenkeTrading
PenkeTrading Apr. 25 at 4:05 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Akeso, Inc.. Is that bullish or bearish? $AKESF #RsiOverbought #PINK
0 · Reply
Latest News on AKESF
No data available.
ChillPill1972
ChillPill1972 Aug. 11 at 11:04 AM
$SMMT $AKESF Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy In previous studies focused on extensive-stage SCLC (ES-SCLC), ivonescimab has demonstrated its ability to prolong progression-free survival (PFS), combining the synergistic benefits of PD-1/L1 inhibitors and anti-angiogenic agents. Ivonescimab is a cornerstone in Akeso's "IO 2.0" strategy, and Akeso has already initiated a series of Phase III and Phase II clinical trials investigating ivonescimab as a first-line treatment across multiple cancer indications. The initiation of a Phase III study of ivonescimab for LS-SCLC is another key step in extending Akeso's "IO 2.0" approach to earlier stages of lung cancer.
0 · Reply
ChillPill1972
ChillPill1972 Jul. 24 at 2:01 PM
$SMMT $AKESF Akeso having a big month of new trials starting across multiple cancer types which should compliment Summits efforts nicely.
0 · Reply
ChillPill1972
ChillPill1972 Jul. 4 at 11:58 AM
$SMMT $AKESF had a great week, sitting at alltime high. Happy 4th of July!!
0 · Reply
ChillPill1972
ChillPill1972 Jul. 3 at 3:23 PM
$SMMT $AKESF PR today: (not related to the summit news) Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy https://www.prnewswire.com/news-releases/akesos-first-bispecific-adc-trop2nectin4-adc-enters-clinical-trials-strengthening-leadership-in-ioadc-2-0-strategy-302497499.html
0 · Reply
ChillPill1972
ChillPill1972 Jul. 3 at 11:30 AM
$SMMT $AKESF with a strong finish to their day and an alltime high. US markets close at 1pm today for a long weeknd perhaps we get some news soon.
0 · Reply
JRobb66
JRobb66 Jun. 14 at 9:54 AM
$AKESF does this trade? Or what’s the story here
0 · Reply
Bornjever
Bornjever Apr. 25 at 8:14 PM
$AKESF so some persons wrote these guys got FDA approval but not true correct??? After they get stage two from FDA then a year to get stage 3 and then 8 months to get PDUFA. It takes forever. But folks can die or go to China.
0 · Reply
jvj19
jvj19 Apr. 25 at 5:56 PM
$SMMT why isn’t $AKESF trending after they received FDA approval?
3 · Reply
jvj19
jvj19 Apr. 25 at 5:28 PM
$SMMT $AKESF is open to trade.
0 · Reply
PenkeTrading
PenkeTrading Apr. 25 at 4:05 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Akeso, Inc.. Is that bullish or bearish? $AKESF #RsiOverbought #PINK
0 · Reply
Onyx99
Onyx99 Feb. 27 at 6:16 AM
$AKESF in the news today: ‘Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than 130 US billion dollars in sales…’ Anyone to comment on this? By all means, if this can do 130 US billion surely this stock is a goldmine waiting to be collected.
0 · Reply
SteakNmilk
SteakNmilk Feb. 13 at 5:46 PM
$SMMT is the partnership with $AKESF all inclusive? Or only on select drugs?
0 · Reply
SteakNmilk
SteakNmilk Feb. 13 at 5:45 PM
$AKESF is the partnership with summit all inclusive. Or only on select drugs?
0 · Reply
Diefreeandsell
Diefreeandsell Sep. 13 at 6:09 PM
$SMMT Didn't they know all this since Aug 28 . News is kinda stale now, no? Maybe buy Akeso $AKESF shares instead? https://finance.yahoo.com/news/akesos-2024-first-half-interim-202000069.html
1 · Reply
fda_tracker
fda_tracker Aug. 5 at 1:05 PM
$AKESF Phase 2 trial w/est Aug completion date NCT06061471: https://www.clinicaltrials.gov/study/NCT06061471 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
fda_tracker
fda_tracker Jun. 5 at 1:05 PM
$AKESF Phase 2 trial w/est Jun completion date NCT05687851: https://www.clinicaltrials.gov/study/NCT05687851 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
Pianomemo
Pianomemo May. 31 at 7:07 AM
$SMMT overall response rate of 68.4% among patients with non-small cell lung cancer Data reported in ASCO23. Merck dethroned $AKESF $XBI $MRK
0 · Reply